EUVIMEDEUVIMED entdecken
Crossref

Ampicillin Pharmacokinetics in Peripartum and Laboring Women

Amy E Judy, Adam Frymoyer, Jessica Ansari, David R Drover, Brendan Carvalho iD

American Journal of Perinatology · 01.01.2024 · 41 (02) · 127-133

DOI: 10.1055/a-1674-6394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.01.2024. Verfasst von Amy E Judy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California. Hauptthemen laut MEDLINE: Chorioamnionitis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Ampicillin is used for multiple peripartum indications including prevention of neonatal group B streptococcus (GBS) and treatment of chorioamnionitis. Despite its widespread use in obstetrics, existing pharmacokinetic data for ampicillin do not address contemporary indications or dosing paradigms for this population. We sought to characterize the pharmacokinetic profile of ampicillin administered to laboring women. Study Design Using whole blood dried blood spot sampling technique, maternal blood samples were collected at specified times from 31 women receiving intravenous (IV) ampicillin for peripartum indications. Women received either a 2-g loading dose with 1-g administered every 4 hours (GBS) or 2-g every 6 hours (chorioamnionitis). Pharmacokinetics were analyzed via a population approach with nonlinear mixed-effect modeling.

Results

The data were best described by a two-compartment model with first-order elimination, with the following whole blood parameters: central volume of distribution (V1), 75.2 L (95% confidence interval [CI]: 56.3–93.6); clearance (CL), 82.4 L/h (95% CI: 59.7–95.7); intercompartmental clearance (Q), 20.9 L/h (95% CI: 16.2–38.2); and peripheral volume of distribution (V2), 61.1 L (95% CI: 26.1–310.5). Interpatient variation in CL and V1 was large (42.0 and 56.7%, respectively). Simulations of standard dosing strategies demonstrated over 98% of women are predicted to achieve an estimated free plasma concentration above mean inhibitory concentration (MIC) of 0.5 μg/mL for more than 50% of the dosing interval.

Conclusion

Although large variation in the pharmacokinetics of ampicillin in pregnant women exists, as predicted by our model, current standard dosing strategies achieve adequate exposure for GBS in nearly all patients. Key Points

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChorioamnionitisPregnancyInfant, NewbornHumansFemalePeripartum PeriodAmpicillinAdministration, IntravenousAnti-Bacterial Agents

Substanzen

AmpicillinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California.
  • Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
  • Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California.

ORCID-Profile: Brendan Carvalho

Zitieren

APA

Judy, A. E., Frymoyer, A., Ansari, J., Drover, D. R., & Carvalho, B. (2024). Ampicillin Pharmacokinetics in Peripartum and Laboring Women. American Journal of Perinatology, 41(02), 127-133. https://doi.org/10.1055/a-1674-6394

Vancouver

Judy AE, Frymoyer A, Ansari J, Drover DR, Carvalho B. Ampicillin Pharmacokinetics in Peripartum and Laboring Women. American Journal of Perinatology. 2024;41(02):127-133. doi:10.1055/a-1674-6394

BibTeX
@article{Judy2024,
  author = {Judy, Amy E and Frymoyer, Adam and Ansari, Jessica and Drover, David R and Carvalho, Brendan},
  title = {Ampicillin Pharmacokinetics in Peripartum and Laboring Women},
  journal = {American Journal of Perinatology},
  year = {2024},
  volume = {41},
  number = {02},
  pages = {127--133},
  doi = {10.1055/a-1674-6394}
}
Kostenlos starten →